genedrive plc (AIM:GDR)
London · Delayed Price · Currency is GBP · Price in GBX 1.076
+0.126 (13.26%)
May 8, 2026, 4:24 PM GMT
genedrive Earnings Call Transcripts
Fiscal Year 2025
-
Rapid pharmacogenetic tests for emergency care are gaining traction, with FY25 revenue reaching GBP 1 million and strong clinical adoption in the U.K. and abroad. Regulatory progress, pilot programs, and new funding position the company for further growth, though additional capital is needed.
Fiscal Year 2024
-
Revenue grew to GBP 500,000 as adoption of two innovative pharmacogenetic tests increased, though losses widened due to R&D and scaling costs. Regulatory progress, strong clinical endorsements, and expanding international traction position the company for future growth.